| pubmed-article:7540207 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7540207 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:7540207 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:7540207 | lifeskim:mentions | umls-concept:C0032824 | lld:lifeskim |
| pubmed-article:7540207 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:7540207 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:7540207 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:7540207 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:7540207 | pubmed:dateCreated | 1995-7-18 | lld:pubmed |
| pubmed-article:7540207 | pubmed:abstractText | The in vitro biological characterization of a series of 4-(alkylamino)-1,4-dihydroquinolines is reported. These compounds are novel inhibitors of voltage-activated n-type potassium ion (K+) channels in human T lymphocytes. This series, identified from random screening, was found to inhibit [125I]charybdotoxin binding to n-type K+ channels with IC50 values ranging from 10(-6) to 10(-8) M. These analogs also inhibit whole cell n-type K+ currents with IC50 values from 10(-5) to 10(-7) M. The preparation of a series of new 4-(alkylamino)-1,4-dihydroquinolines is described. Structure-activity relationships are discussed. Naphthyl analog 7c, the best compound prepared, exhibited > 100-fold selectivity for inhibition of [125I]charybdotoxin binding to n-type K+ channels compared with inhibition of [3H]dofetilide binding to cardiac K+ channels. These compounds represent a potent and selective series of n-type K+ channel inhibitors that have the potential for further development as anti-inflammatory agents. | lld:pubmed |
| pubmed-article:7540207 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7540207 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7540207 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7540207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7540207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7540207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7540207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7540207 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7540207 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7540207 | pubmed:month | May | lld:pubmed |
| pubmed-article:7540207 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:7540207 | pubmed:author | pubmed-author:MichneW FWF | lld:pubmed |
| pubmed-article:7540207 | pubmed:author | pubmed-author:GrantA MAM | lld:pubmed |
| pubmed-article:7540207 | pubmed:author | pubmed-author:TreasurywalaA... | lld:pubmed |
| pubmed-article:7540207 | pubmed:author | pubmed-author:ChadwickC CCC | lld:pubmed |
| pubmed-article:7540207 | pubmed:author | pubmed-author:KrafteD SDS | lld:pubmed |
| pubmed-article:7540207 | pubmed:author | pubmed-author:VolbergW AWA | lld:pubmed |
| pubmed-article:7540207 | pubmed:author | pubmed-author:GuilesJ WJW | lld:pubmed |
| pubmed-article:7540207 | pubmed:author | pubmed-author:CastonguayL... | lld:pubmed |
| pubmed-article:7540207 | pubmed:author | pubmed-author:WeigeltC ACA | lld:pubmed |
| pubmed-article:7540207 | pubmed:author | pubmed-author:OconnorBB | lld:pubmed |
| pubmed-article:7540207 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7540207 | pubmed:day | 26 | lld:pubmed |
| pubmed-article:7540207 | pubmed:volume | 38 | lld:pubmed |
| pubmed-article:7540207 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7540207 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:7540207 | pubmed:pagination | 1877-83 | lld:pubmed |
| pubmed-article:7540207 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7540207 | pubmed:meshHeading | pubmed-meshheading:7540207-... | lld:pubmed |
| pubmed-article:7540207 | pubmed:meshHeading | pubmed-meshheading:7540207-... | lld:pubmed |
| pubmed-article:7540207 | pubmed:meshHeading | pubmed-meshheading:7540207-... | lld:pubmed |
| pubmed-article:7540207 | pubmed:meshHeading | pubmed-meshheading:7540207-... | lld:pubmed |
| pubmed-article:7540207 | pubmed:meshHeading | pubmed-meshheading:7540207-... | lld:pubmed |
| pubmed-article:7540207 | pubmed:meshHeading | pubmed-meshheading:7540207-... | lld:pubmed |
| pubmed-article:7540207 | pubmed:meshHeading | pubmed-meshheading:7540207-... | lld:pubmed |
| pubmed-article:7540207 | pubmed:meshHeading | pubmed-meshheading:7540207-... | lld:pubmed |
| pubmed-article:7540207 | pubmed:meshHeading | pubmed-meshheading:7540207-... | lld:pubmed |
| pubmed-article:7540207 | pubmed:meshHeading | pubmed-meshheading:7540207-... | lld:pubmed |
| pubmed-article:7540207 | pubmed:meshHeading | pubmed-meshheading:7540207-... | lld:pubmed |
| pubmed-article:7540207 | pubmed:meshHeading | pubmed-meshheading:7540207-... | lld:pubmed |
| pubmed-article:7540207 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7540207 | pubmed:articleTitle | Novel inhibitors of potassium ion channels on human T lymphocytes. | lld:pubmed |
| pubmed-article:7540207 | pubmed:affiliation | Sanofi Winthrop Inc., Collegeville, Pennsylvania 19426, USA. | lld:pubmed |
| pubmed-article:7540207 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7540207 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:7540207 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7540207 | lld:pubmed |
